What is Pertuzumab?

Pertuzumab (Pertuzumab) is a recombinant humanized monoclonal antibody that can target the extracellular dimerization domain of human epidermal growth factor receptor 2 protein (HER2). It is a type of anti-tumor drug and can be used in combination with other anti-tumor drugs to treat HER2-positive metastatic breast cancer. It will be sold under the trade name Perjeta after approval.

Pertuzumab can be administered intravenously in combination with trastuzumab and docetaxel for the treatment of patients with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. It is also indicated for use in the neoadjuvant treatment of HER2-positive locally advanced, inflammatory or early-stage breast cancer in combination with trastuzumab and other chemotherapy, as part of a complete treatment regimen, and as adjuvant treatment in patients with HER2-positive early-stage breast cancer who are at high risk of recurrence. Pertuzumab is also indicated for subcutaneous injection - in combination with trastuzumab and hyaluronidase - for the treatment of HER2-positive breast cancer in adults.

Pertuzumab is a strictly controlled drug. The original drug has been marketed in China and has entered the ranks of medical insurance, but it is only reimbursed for patients who meet the indications. The price of each box may be more than more than 5,000 yuan, and the price of the Hong Kong version may be more than 20,000 yuan (the price may fluctuate due to exchange rates). The price of each box of the European version of Pertuzumab's original drug marketed overseas may be more than 10,000 yuan, and the price of each box of the Turkish version may be more than 6,000 yuan (the price may fluctuate due to exchange rates). The ingredients of the domestic and foreign original drugs are basically the same, and there are currently no generic versions of Pertuzumab on the market.